Summary

for people ages 18 years and up (full criteria)
at UCLA
study started
estimated completion

Description

Summary

Open-label, continuation study

Official Title

An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy

Details

This is a multicenter, open-label, non-randomized, study of TRC105 in patients that have completed a previous TRC105 study and are judged by the investigator to have the potential to benefit from continued TRC105 therapy.

Keywords

Solid Tumors Bevacizumab Capecitabine Axitinib Antibodies, Monoclonal TRC105 Pazopanib

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participation in a TRACON Pharmaceuticals sponsored parent TRC105 study and, thought to have potential to derive clinical benefit from continued treatment with TRC105 in the opinion of the parent study investigator.
  • Willing and able to consent for self to participate in study
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • 18 years of age or older
  • ability to begin TRC105 dosing on this protocol within 6 weeks from the subjects last dose of TRC105 in the parent TRC105 study

You CAN'T join if...

  • Any clinical event that would make TRC105 therapy inappropriate under the parent protocol
  • Current treatment in another clinical study
  • Pregnant or breastfeeding
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator, would make the subject inappropriate for entry into the study

Location

  • UCLA
    Santa Monica California 90404 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Tracon Pharmaceuticals Inc.
ID
NCT02354612
Phase
Phase 1/2
Study Type
Interventional
Last Updated